相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Urology & Nephrology
Maria Rosaria De Cagna et al.
Summary: The study investigated the immune response after BNT162b2 vaccination in hemodialysis (HD) and kidney transplant (RTx) patients. The results showed that HD patients had significantly higher antibody levels after the second dose compared to RTx patients, and the booster dose did not significantly enhance the immune response in most RTx patients.
CLINICAL AND EXPERIMENTAL NEPHROLOGY
(2023)
Review
Immunology
Maria Riastuti Iryaningrum et al.
Summary: This systematic and meta-analysis evaluated the immune responses to the SARS-CoV-2 vaccine in kidney transplant recipients (KTRs). A total of 44 studies involving 5,892 KTRs were included. The overall seroconversion rate was 39.2%, and the cellular response rate was 41.6%. Low antibody response was associated with certain immunosuppressive agents, while tacrolimus use was associated with higher antibody response. Additional doses of a different type of vaccine are recommended for this population.
CLINICAL AND EXPERIMENTAL VACCINE RESEARCH
(2023)
Review
Urology & Nephrology
Saeed Taheri
Summary: This systematic review and meta-analysis evaluated the efficacy of booster dose vaccination in patients undergoing renal replacement therapy. The study found that booster dose vaccination significantly increased seroconversion rates in kidney transplant recipients and enhanced T-cell response. Therefore, implementing booster dose vaccination in patients undergoing renal replacement therapy is safe and effective.
INTERNATIONAL UROLOGY AND NEPHROLOGY
(2023)
Letter
Medicine, General & Internal
Shirley Collie et al.
Summary: Preliminary data from a test-negative study design in South Africa showed that two doses of the BNT162b2 vaccine had an efficacy of 50 to 70% against hospitalization caused by the omicron variant in Gauteng province.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Roman Reindl-Schwaighofer et al.
Summary: Less than 50% of kidney transplant recipients developed antibodies against the SARS-CoV-2 spike protein after 2 doses of an mRNA vaccine. A third dose of either mRNA or vector vaccine increased antibody response in 39% of KTRs without prior immune response, but neutralizing antibodies and T-cell response remained low. Triple immunosuppression, longer time after transplant, and torque teno virus plasma levels were associated with vaccine response. Local pain was higher with mRNA vaccine, but systemic symptoms were similar between groups.
JAMA INTERNAL MEDICINE
(2022)
Article
Transplantation
Hideki Ishida et al.
Summary: This study investigated the changes in antibody levels after BNT162B2 COVID-19 mRNA vaccination in kidney transplant recipients in Japan. The results showed a lower antibody-positive rate in this group compared to healthy controls, and the use of immunosuppressants was found to be associated with the antibody response.
EXPERIMENTAL AND CLINICAL TRANSPLANTATION
(2022)
Letter
Urology & Nephrology
Ayman Al Jurdi et al.
KIDNEY INTERNATIONAL
(2022)
Article
Medicine, General & Internal
Bilgin Osmanodja et al.
Summary: High mortality and impaired response to COVID-19 vaccinations are observed in kidney transplant recipients. Retrospective analysis shows that up to five doses of SARS-CoV-2 vaccine induce serological response in these patients, especially when mycophenolic acid (MPA) is paused.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Transplantation
Hideki Ishida et al.
Summary: Many researchers have shown that patients receiving oral immunosuppressants have a lower seropositivity rate after SARS-CoV-2 coronavirus vaccination. This article reports a comparative study on the seropositivity rate after two doses of coronavirus vaccine before or after kidney transplant. The results suggest that patients vaccinated before transplant and healthy patients have a high seropositivity rate, while only a portion of the recipients vaccinated after transplant developed seropositivity.
EXPERIMENTAL AND CLINICAL TRANSPLANTATION
(2022)
Article
Immunology
Satoshi Takai et al.
Summary: The third dose of the SARS-CoV-2 mRNA vaccine, administered with a longer interval after the second vaccination, improved the humoral and cellular immune responses in kidney transplant recipients (KTRs) without severe adverse effects.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Irene Cassaniti et al.
Summary: This study investigated the role of a third dose of the BNT162b2 vaccine in kidney transplant recipients. The researchers found an increased immune response, especially in terms of T cell response to the Spike protein, after the third dose. However, the seroconversion rate remained below 50%. Mycophenolate treatment, steroid administration, and age appeared to be associated with a poor immune response.
Article
Surgery
Tammy Hod et al.
Summary: Renal transplant recipients (RTR) showed an improved humoral response to the third dose of the BNT162b2 vaccine, with 85.9% developing neutralizing antibodies. Age, diabetic nephropathy as a cause of end-stage renal disease, and renal allograft function were predictors of antibody response. The use and dosage of mycophenolic acid did not affect the humoral response.
TRANSPLANT INTERNATIONAL
(2022)
Article
Surgery
Dafna Yahav et al.
Summary: The immune response to two doses of SARS-CoV-2 mRNA vaccine is limited among kidney transplant recipients. This study aimed to evaluate the humoral and cellular response to a third dose of the BNT162b2 vaccine. The results showed that the third dose improved the immune response among kidney transplant recipients, although 30% of them remained seronegative. Temporary reduction of immunosuppression before vaccination was found to improve the antibody response.
TRANSPLANT INTERNATIONAL
(2022)
Article
Urology & Nephrology
Sumit Mohan et al.
Summary: The study found higher mortality rates associated with COVID-19 among waitlisted kidney transplant candidates and recipients in the United States in 2020. 11% of deaths among waitlisted candidates and 16% of deaths among active transplant recipients were attributed to COVID-19. Additionally, there was higher overall mortality in 2020 among waitlisted candidates (24%) compared to kidney transplant recipients (20%).
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2021)
Article
Multidisciplinary Sciences
Eric H. Y. Lau et al.
Summary: In this study, researchers quantified SARS-CoV-2 specific neutralizing antibodies using plaque reduction neutralization (PRNT) assays on 195 patients in different disease states. They found that patients with severe disease had higher peaks of neutralizing antibody titres than patients with mild or asymptomatic infections, and that serum neutralizing antibody persists for over 6 months in most people.
NATURE COMMUNICATIONS
(2021)
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Article
Virology
Johannes Korth et al.
Summary: Research has shown that renal transplant recipients have impaired immune response after receiving two doses of mRNA-based vaccine, with significantly lower antibody levels compared to healthy controls.
Letter
Medicine, General & Internal
Ilies Benotmane et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Urology & Nephrology
Dominique Bertrand et al.
Summary: Immunization with BNT162b2 appears to be more effective in HDPs, with the immune response in KTRs potentially influenced by immunosuppressive medications. Current vaccinal strategies for KTRs may not provide adequate protection against COVID-19 and may need further improvement.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2021)
Article
Urology & Nephrology
Clement Danthu et al.
Summary: The study shows that kidney transplant recipients have a strong inhibition of humoral response to COVID-19 vaccination due to immunosuppressant therapy, while patients undergoing hemodialysis have lower antibody levels. Factors such as age, serum albumin, and Kt/V can impact the level of antibody response.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2021)
Letter
Medicine, General & Internal
Nassim Kamar et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Moriah Bergwerk et al.
Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Urology & Nephrology
Maria Prendecki et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2020)
Article
Medicine, General & Internal
Kfir Oved et al.
Article
Immunology
Rabab Al Attas et al.
TRANSPLANTATION PROCEEDINGS
(2019)
